



PB 22 of 2025

National Health (Minimum Stockholding) Amendment Determination (No. 2) 2025

I, Rebecca Richardson, as delegate of the Minister for Health and Aged Care, make the following determination.

Dated 24 February 2025

Rebecca Richardson
Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health and Aged Care

Contents

1 Name	1
2 Commencement.....	1
3 Authority	1
4 Schedules.....	1
Schedule 1—Amendments commencing 1 March 2025	2
<i>National Health (Minimum Stockholding) Determination 2023</i>	2
Schedule 2—Amendments commencing 1 August 2025	14
<i>National Health (Minimum Stockholding) Determination 2023</i>	14

1 Name

- (1) This instrument is the *National Health (Minimum Stockholding) Amendment Determination (No. 2) 2025*.
- (2) This instrument may also be cited as PB 22 of 2025.

2 Commencement

- (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information		
Column 1	Column 2	Column 3
Provisions	Commencement	Date/Details
1. Sections 1 to 4 and anything in this instrument not elsewhere covered by this table	1 March 2025.	1 March 2025
2. Schedule 1	1 March 2025.	1 March 2025
3. Schedule 2	1 August 2025.	1 August 2025

- (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under subsection 99AEKC(2) of the *National Health Act 1953*.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments commencing 1 March 2025

National Health (Minimum Stockholding) Determination 2023

1 Schedule 1 (table)

Omit:

Amitriptyline	Tablet containing amitriptyline hydrochloride 25 mg	Oral	APX-Amitriptyline	(a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand (b) after 31 December 2023—5 months stock by reference to usual demand
---------------	---	------	-------------------	--

substitute:

Amitriptyline	Tablet containing amitriptyline hydrochloride 25 mg	Oral	APX-Amitriptyline	5 months stock by reference to usual demand
---------------	---	------	-------------------	---

2 Schedule 1 (table)

Omit:

Amitriptyline	Tablet containing amitriptyline hydrochloride 50 mg	Oral	APX-Amitriptyline	(a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand (b) after 31 December 2023—4.5 months stock by reference to usual demand
---------------	---	------	-------------------	--

Amitriptyline	Tablet containing amitriptyline hydrochloride 50 mg	Oral	ENTRIP	(a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand (b) after 31 December 2023—4.5 months stock by reference to usual demand
---------------	---	------	--------	--

	substitute:			
Amitriptyline	Tablet containing amitriptyline hydrochloride 50 mg	Oral	APX-Amitriptyline	4.5 months stock by reference to usual demand
Amitriptyline	Tablet containing amitriptyline hydrochloride 50 mg	Oral	ENTRIP	4.5 months stock by reference to usual demand

3 Schedule 1 (table item dealing with the drug Codeine, column number 4)

Omit “Aspen Pharma Pty Ltd”, substitute “Aspen Pharmacare Australia Pty Ltd”.

4 Schedule 1 (table)

Omit:

Doxycycline	Tablet 100 mg (as hyclate)	Oral	APX-Doxycycline	(a) between 1 July 2023 and 31 December 2023—4.5 months stock by reference to usual demand (b) after 31 December 2023—5.5 months stock by reference to usual demand
-------------	----------------------------	------	-----------------	--

substitute:

Doxycycline	Tablet 100 mg (as hyclate)	Oral	APX-Doxycycline	5.5 months stock by reference to usual demand
-------------	----------------------------	------	-----------------	---

5 Schedule 1 (table)

Omit:

Enalapril	Tablet containing enalapril maleate 5 mg	Oral	Acetec	(a) between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand (b) after 31 December 2023—2 months stock by reference to usual demand
-----------	--	------	--------	--

substitute:

Enalapril	Tablet containing enalapril maleate 5 mg	Oral	Acetec	2 months stock by reference to usual demand
-----------	--	------	--------	---

6 Schedule 1 (table)

	Omit:				
Fentanyl	Transdermal patch 10.20 mg	Transdermal	Denpax	(a) between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand (b) after 31 December 2023—2.5 months stock by reference to usual demand	
	substitute:				
Fentanyl	Transdermal patch 10.20 mg	Transdermal	Denpax	2.5 months stock by reference to usual demand	

7 Schedule 1 (table)

	Omit:				
Fentanyl	Transdermal patch 2.1 mg	Transdermal	APO-Fentanyl	(a) between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand (b) after 31 December 2023—3.5 months stock by reference to usual demand	
	substitute:				
Fentanyl	Transdermal patch 2.1 mg	Transdermal	APO-Fentanyl	3.5 months stock by reference to usual demand	

8 Schedule 1 (table)

	Omit:				
Fentanyl	Transdermal patch 5.10 mg	Transdermal	Denpax	(a) between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand (b) after 31 December 2023—2.5 months stock by	

				reference to usual demand
	substitute:			
Fentanyl	Transdermal patch 5.10 mg	Transdermal	Denpax	2.5 months stock by reference to usual demand

9 Schedule 1 (table)

	Omit:			
Galantamine	Capsule (prolonged release) 8 mg (as hydrobromide)	Oral	Galantyl	(a) between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand (b) after 31 December 2023—1.5 months stock by reference to usual demand
	substitute:			
Galantamine	Capsule (prolonged release) 8 mg (as hydrobromide)	Oral	Galantyl	1.5 months stock by reference to usual demand

10 Schedule 1 (table)

	Omit:			
Irbesartan	Tablet 150 mg	Oral	Irbesartan GH	between 1 November 2024 and 28 February 2025—0 months stock by reference to usual demand
Irbesartan	Tablet 300 mg	Oral	Irbesartan GH	between 1 November 2024 and 28 February 2025—0 months stock by reference to usual demand

11 Schedule 1 (table)

	Omit:			
Lansoprazole	Tablet 15 mg (orally disintegrating)	Oral	APO-Lansoprazole ODT	(a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand (b) after 31 December

2023—4.5
months stock by
reference to usual
demand

substitute:

Lansoprazole	Tablet 15 mg (orally disintegrating)	Oral	APO-Lansoprazole ODT	4.5 months stock by reference to usual demand
--------------	--------------------------------------	------	----------------------	---

12 Schedule 1 (table)

After:

Letrozole	Tablet 2.5 mg	Oral	Letrozole APOTEX	4 months stock by reference to usual demand of both Letrozole APOTEX and ARX-LETROZOLE added together
-----------	---------------	------	------------------	---

insert:

Levetiracetam	Tablet 1 g	Oral	Levetiracetam Viatriis	after 31 June 2025—4 months stock by reference to usual demand of both Levetiracetam Viatriis and Levetiracetam Mylan added together
---------------	------------	------	------------------------	--

Levetiracetam	Tablet 250 mg	Oral	Levetiracetam Viatriis	after 31 June 2025—4 months stock by reference to usual demand of both Levetiracetam Viatriis and Levetiracetam Mylan added together
---------------	---------------	------	------------------------	--

13 Schedule 1 (table)

After:

Lithium	Tablet containing lithium carbonate 450 mg (slow release)	Oral	Quilonum SR	6 months stock by reference to usual PBS demand
---------	---	------	-------------	---

insert:

Macrogol 3350	Sachets containing powder for oral solution 13.125 g with electrolytes, 30	Oral	Chemists' Own Macrogol with Electrolytes	between 1 March 2025 and 30 April 2025—0 months stock by reference to usual demand
---------------	--	------	--	--

14 Schedule 1 (table)

Omit:					
Nicorandil	Tablets 10 mg, 60	Oral	Ikotab	(a) between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand (b) after 31 December 2023—2 months stock by reference to usual demand	
substitute:					
Nicorandil	Tablets 10 mg, 60	Oral	Ikotab	2 months stock by reference to usual demand	

15 Schedule 1 (table)

Omit:					
Nicorandil	Tablets 20 mg, 60	Oral	Ikotab	(a) between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand (b) after 31 December 2023—2 months stock by reference to usual demand	
substitute:					
Nicorandil	Tablets 20 mg, 60	Oral	Ikotab	2 months stock by reference to usual demand	

16 Schedule 1 (table)

Omit:					
Olanzapine	Tablet 15 mg (orally disintegrating)	Oral	PRYZEX ODT	(a) between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand (b) after 31 December 2023—3.5 months stock by	

				reference to usual demand
	substitute:			
Olanzapine	Tablet 15 mg (orally disintegrating)	Oral	PRYZEX ODT	3.5 months stock by reference to usual demand

17 Schedule 1 (table)

	Omit:			
Olmesartan	Tablet containing olmesartan medoxomil 40 mg	Oral	OLMERTAN	(a) between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand (b) after 31 December 2023—3.5 months stock by reference to usual demand

	substitute:			
Olmesartan	Tablet containing olmesartan medoxomil 40 mg	Oral	OLMERTAN	3.5 months stock by reference to usual demand

18 Schedule 1 (table)

	Omit:			
Pantoprazole	Tablet (enteric coated) 20 mg (as sodium sesquihydrate)	Oral	APO-Pantoprazole	(a) between 1 July 2023 and 31 December 2023—4.5 months stock by reference to usual demand (b) after 31 December 2023—5.5 months stock by reference to usual demand

	substitute:			
Pantoprazole	Tablet (enteric coated) 20 mg (as sodium sesquihydrate)	Oral	APO-Pantoprazole	5.5 months stock by reference to usual demand

19 Schedule 1 (table)

Omit:				
Pantoprazole	Tablet (enteric coated) 40 mg (as sodium sesquihydrate)	Oral	Sozol	(a) between 1 July 2023 and 31 December 2023—4.5 months stock by reference to usual demand (b) after 31 December 2023—5.5 months stock by reference to usual demand
substitute:				
Pantoprazole	Tablet (enteric coated) 40 mg (as sodium sesquihydrate)	Oral	Sozol	5.5 months stock by reference to usual demand

20 Schedule 1 (table)

Omit:				
Perindopril	Tablet containing perindopril erbumine 2 mg	Oral	Indosyl Mono 2	(a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand (b) after 31 December 2023—5 months stock by reference to usual demand
Perindopril	Tablet containing perindopril erbumine 4 mg	Oral	Indosyl Mono 4	(a) between 1 July 2023 and 31 December 2023—4.5 months stock by reference to usual demand (b) after 31 December 2023—5.5 months stock by reference to usual demand
Perindopril with indapamide	Tablet containing perindopril erbumine 4 mg with indapamide hemihydrate 1.25 mg	Oral	Indosyl Combi 4/1.25	(a) between 1 July 2023 and 31 December 2023—4 months stock by

				reference to usual demand
				(b) after 31 December 2023—5 months stock by reference to usual demand
Perindopril with indapamide	Tablet containing perindopril erbumine 4 mg with indapamide hemihydrate 1.25 mg	Oral	Perindo Combi 4/1.25	(a) between 1 July 2023 and 31 December 2023—2 months stock by reference to usual demand (b) after 31 December 2023—2.5 months stock by reference to usual demand

21 Schedule 1 (table)

	After:			
Periciazine	Tablet 2.5 mg	Oral	Neulactil	6 months stock by reference to usual PBS demand
	insert:			
Perindopril	Tablet containing perindopril erbumine 2 mg	Oral	Indosyl Mono 2	between 1 March 2025 and 30 April 2025—0 months stock by reference to usual demand
Perindopril	Tablet containing perindopril erbumine 4 mg	Oral	Indosyl Mono 4	between 1 March 2025 and 30 April 2025—0 months stock by reference to usual demand
Perindopril	Tablet containing perindopril erbumine 8 mg	Oral	Indosyl Mono 8	between 1 March 2025 and 30 April 2025—0 months stock by reference to usual demand
Perindopril with indapamide	Tablet containing perindopril erbumine 4 mg with indapamide hemihydrate 1.25 mg	Oral	Indosyl Combi 4/1.25	between 1 March 2025 and 30 April 2025—0 months stock by reference to usual demand
Perindopril with indapamide	Tablet containing perindopril erbumine 4 mg with indapamide hemihydrate 1.25 mg	Oral	Perindo Combi 4/1.25	2.5 months stock by reference to usual demand

22 Schedule 1 (table)

Omit:

Pregabalin	Capsule 150 mg	Oral	Cipla Pregabalin	between 1 October 2024 and 28 February 2025—0 months stock by reference to usual demand
------------	----------------	------	------------------	---

23 Schedule 1 (table)

Omit:

Ramipril	Capsule 10 mg	Oral	APX-Ramipril	(a) between 1 July 2023 and 31 December 2023—4.5 months stock by reference to usual demand (b) after 31 December 2023—5.5 months stock by reference to usual demand
----------	---------------	------	--------------	--

Ramipril	Capsule 10 mg	Oral	Prilace	(a) between 1 July 2023 and 31 December 2023—4.5 months stock by reference to usual demand (b) after 31 December 2023—5.5 months stock by reference to usual demand
----------	---------------	------	---------	--

substitute:

Ramipril	Capsule 10 mg	Oral	APX-Ramipril	5.5 months stock by reference to usual demand
----------	---------------	------	--------------	---

Ramipril	Capsule 10 mg	Oral	Prilace	5.5 months stock by reference to usual demand
----------	---------------	------	---------	---

24 Schedule 1 (table)

Omit:

Risperidone	Tablet 3 mg	Oral	APO-Risperidone	(a) between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand (b) after 31 December 2023—3.5 months stock by reference to usual demand
-------------	-------------	------	-----------------	--

substitute:

Risperidone	Tablet 3 mg	Oral	APO-Risperidone	3.5 months stock by reference to usual demand
-------------	-------------	------	-----------------	---

25 Schedule 1 (table)

Omit:

Roxithromycin	Tablet 300 mg	Oral	APX-Roxithromycin	(a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand (b) after 31 December 2023—5 months stock by reference to usual demand
---------------	---------------	------	-------------------	--

substitute:

Roxithromycin	Tablet 300 mg	Oral	APX-Roxithromycin	5 months stock by reference to usual demand
---------------	---------------	------	-------------------	---

26 Schedule 1 (table)

Omit:

Sotalol	Tablet containing sotalol hydrochloride 160 mg	Oral	Cardol	(a) between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand (b) after 31 December 2023—1.5 months stock by
---------	--	------	--------	--

reference to usual demand

Sotalol	substitute: Tablet containing sotalol hydrochloride 160 mg	Oral	Cardol	1.5 months stock by reference to usual demand
---------	---	------	--------	---

27 Schedule 1 (table)

Omit:

Valine with carbohydrate	Sachets of oral powder 4 g containing 1 g valine, 30 (Valine 1000)	Oral	Valine 1000	after 30 November 2024—0 months stock by reference to usual PBS demand
Valine with carbohydrate	Sachets of oral powder 4 g containing 50 mg valine, 30 (Valine 50)	Oral	Valine 50	after 30 November 2024—0 months stock by reference to usual PBS demand
Valine with carbohydrate	substitute: Sachets of oral powder 4 g containing 1 g valine, 30 (Valine 1000)	Oral	Valine 1000	0 months stock by reference to usual PBS demand
Valine with carbohydrate	Sachets of oral powder 4 g containing 50 mg valine, 30 (Valine 50)	Oral	Valine 50	0 months stock by reference to usual PBS demand

Schedule 2—Amendments commencing 1 August 2025

National Health (Minimum Stockholding) Determination 2023

1 Schedule 1 (table)

	After:				
Ciclosporin	Oral liquid 100 mg per mL, 50 mL	Oral	Neoral		4 months stock by reference to usual PBS demand
	insert:				
Ciprofloxacin	Ear drops 3 mg (as hydrochloride) per mL, 5 mL	Application to the Ear	Ciloxan		6 months stock by reference to usual PBS demand

2 Schedule 1 (table)

	After:				
Methoxyflurane	Liquid for inhalation 999 mg per g, 3 ml (with inhaler)	Inhalation by mouth	Penthrox (Combination Pack)		6 months stock by reference to usual PBS demand
	insert:				
Metoclopramide	Injection containing 10 mg metoclopramide hydrochloride (as monohydrate) in 2 mL	Injection	Metoclopramide HCl Medsurge		6 months stock by reference to usual demand